The jack jumper ant, Myrmecia pilosula, is endemic to South-Eastern Australia, where around 2.7% of the population has a history of systemic allergic reactions (anaphylaxis) to its venom. Previous work had indicated that there were several allergenic peptides derived from the cDNA Myr p 1, the major expressed allergenic product being a 56-residue peptide (Myr p 1 57→112, "pilosulin 1", ~6052 Da).
Introduction:
The "Jack Jumper" ant (Myrmecia pilosula species complex), is a commonly encountered member of the genus Myrmecia ("bulldog" and "jumper" ants, Hymenoptera: Formicidae: Myrmeciinae) found in southeastern Australia including Tasmania and the southernmost tip of Western Australia (Ogata and Taylor, 1991) . In Tasmania, 2.7% of the population has a history of systemic allergic reactions to jack jumper venom (Brown et al., 2003a) and around half of allergic people experience life-threatening reactions (Brown et al., 2003a; Clarke 1986; Douglas at al., 1998) .
Deaths have been reported (Brown et al., 2001) , and the venom appears to be particularly allergenic in comparison to other venoms; in people with a history of wasp and bee sting allergy, only 25-50% react to subsequent deliberate sting challenges (van Haltern et al., 1996) , whereas re-sting reaction rates in people with jack jumper sting allergy are 70% for field stings (Brown et al., 2003a) and 72% for deliberate sting challenges (Brown et al., 2003b) . M. pilosula venom has been shown to contain histamine-like, haemolytic, and eicosanoid releasing factors, and to have a broad range of enzymatic activity including phospholipase A2, phospholipase B, hyaluronidase, acid phosphatase and alkaline phosphatase (Matuszek et al., 1992; Matuszek et al., 1994) .
Previously thought to be a single species, M. pilosula is in fact a karyologically diverse species complex, consisting of several sibling species (Crozier et al., 1995; Crosland et al., 1988 ) that may even coexist at a single site (Taylor, 1988) . It has nevertheless been claimed that IgE binding profiles of electrophoretically separated venoms from different regions of Australia, and thus "presumably" from different sibling species, are identical (Ford et al., 1991) .
Two major protein allergens sharing a common leader sequence have been identified via cDNA sequencing (Donovan et al., 1993; Donovan et al., 1994; Donovan et al., 1995; Street et al., 1996) , and found to encode 112 and 75 amino acid residues. The cDNA has been named Myr p 1 and Myr p 2 respectively (Figures 1a and 1b) . These encode precursor peptides that differ by only three amino acids in the first 47 residues. However, both appear to undergo extensive post-translational modification. Donovan et al. (1996) have proposed (using SDS-PAGE, immunoblotting and 8 cycles of N-terminal amino acid sequencing) that whole venom contains six subsequences of Myr p 1 (figure 1c), the major IgE binding band being Myr p 1 57→112. Two other predicted peptide cleavage products of Myr p 1 27→112 and Myr p 1 37→112 were not identified in whole venom.
IgE binding bands at 8.5kDa and a broad band at 2-4kDa have been identified as being due to the presence of Myr p 2 derived peptides (Donovan et al., 1995) .
Reduction and alkylation of whole venom revealed a single band, which was presumed (on the basis of 8 cycles of N-terminal amino acid sequencing) to contain Myr p 2 49→75 (Street et al., 1996) . The dual recognition of Myr p 2 is thought to be due to the presence of multimeric forms of Myr p 2 49→75 within whole venom (Street et al., 1996) and given that Myr p 2 49→75 contains 2 cysteine residues, the 8.5kDa peptide was proposed to contain Myr p 2 49→75 in a disulfide linked complex -either with itself or with another non-allergenic peptide(s) (Donovan et al., 1996) .
Myr p 2 27→75 was previously proposed as a product but was subsequently not identified in whole venom via SDS-PAGE (Donovan et al,. 1996) . Myr p 1 57→112 and Myr p 2 49→75 are proposed allergenic products (Donovan et al., 1996) which have been named "pilosulin 1" (Wu et al., 1998; Donovan and Baldo, 1999) and "pilosulin 2" respectively (Donovan and Baldo, 1997). From here on the pilosulin nomenclature will be used when referring to these peptides.
Pilosulin 1 and pilosulin 2 are extremely basic peptides, with 20% and 33% of their residues respectively being lysines or arginines -their theoretical isoelectric points are 9.94 and 10.45 respectively (http://ca.expasy.org/tools/pi_tool.html). Pilosulin 1 has been reported to have significant cytotoxic effects (King et al., 1998; Wu et al., 1998) , and pilosulin 2 has been reported to have antihypertensive properties (Donovan and Baldo, 1997).
We recently published a double-blind placebo-controlled trial of jack jumper ant venom immunotherapy showing this treatment to be highly efficacious in preventing sting anaphylaxis (Brown et al., 2003b) . With the aim of establishing a quality control regime for our venom extracts, we undertook HPLC-MS analysis of the venom, detailed tandem mass spectrometry (MS/MS) sequencing on key peptides and limited Edman sequencing to confirm previous reports of venom composition, and to directly Venom collection and storage M. pilosula were harvested from a variety of locations around Tasmania for venom extraction by either electrostimulation or venom sac dissection. Electrostimulation was performed in the field; live ants were harvested and transferred to a customised perspex box. An alternating current was applied across a steel wire grid, inducing them to sting a glass plate below, on which the venom rapidly dried. The plates were stored on dry ice until return to the laboratory where venom was washed from the plates, centrifuged to remove particulate matter, sterilised by filtration through a 0.22 micron low protein binding filter, lyophilised and weighed to ascertain total peptide/protein content. Venom was redissolved in water for injection to produce a 10mg/ml solution. Aliquots of an amount necessary to formulate pharmaceutical batches were prepared and the solutions stored at -80˚C until required.
Ants destined for venom sac dissection were transferred live to the laboratory where they were snap frozen and stored at -80˚C. Later the ants were defrosted and under aseptic conditions their venom sacs were removed using a dissecting microscope and placed in sterile pyrogen-free polypropylene tubes containing water for injection BP.
Collections of dissected sacs were kept at 0-4 ˚C for no more than 1 hour before being refrozen to -80˚C. When at least 3000 sacs had been dissected, the collections were defrosted; sacs ruptured using a tissue homogeniser and then processed in the same way as electrostimulation venom. Venom collected by electrostimulation was not mixed with venom collected via sac dissection at any time.
Fresh samples prepared by both electrostimulation and sac dissection were used for HPLC-MS analyses, as were lyophilised samples prepared for therapeutic use. For the latter, 10mg/ml venom aliquots were removed from the -80˚C freezer, mixed with mannitol and dispensed into 50 or 120 µg aliquots (each containing 20mg mannitol).
These aliquots were then lyophilised, vacuum-sealed and stored at -8˚C.
HPLC-MS
HPLC analyses were carried out on a Waters Alliance 2690 HPLC, using an Agilent Zorbax 300SB-C3 5µm column (2.1mm x 150mm). The solvent system was; Solvent A: acetonitrile, Solvent B: 1% trifluoracetic acid, Solvent C: water. The flow rate was 0.3ml/min. A linear gradient from 10% A, 8% B, 82% C to 70% A, 8% B, 22% C at 30 min was used in most cases. A slower gradient from 15% A, 8% B, 77% C to 50% A, 8% B 43% C at 35 min was used to facilitate specific separations. This was followed by a linear gradient to 92% A, 8% B at 45 minutes to flush the column.
The effluent from the HPLC was directly coupled to a Finnigan LCQ equipped with a standard electrospray source. The needle Voltage was 5KV, the capillary temperature was 250ºC, sheath gas was 70psi and auxiliary gas was 20psi. The range from m/z 100 to 2000 was typically monitored.
The LC effluent was routinely 'supercharged' by post-column addition of 5 ul per minute of a 20% glycerol solution (Iavarone et al., 2001 ). This dramatically increased the abundance of higher charge states, making it less likely that larger peptides might fall outside the m/z range of the LCQ, and also significantly increased overall sensitivity. Charge states of all key ions were confirmed by higher resolution "zoom scans", using peptides collected by HPLC and subsequent direct infusion still in the collection solvent into the electrospray source at 5 ul per minute.
HPLC-UV and Peptide Purification
HPLC-UV profiles of venom samples were obtained using a Waters 996 diode array UV-Vis detector, monitoring wavelengths from 210 to 290 nm. Chromatograms at 220nm and 280nm were generated from this data. Venom peptides were collected from the HPLC effluent (while monitoring the absorbance at 220nm) for subsequent reduction, Edman sequencing, trypsin digestion and Q-TOF MS analyses. These fractions were stored at -50ºC immediately after collection, and evaporated to dryness at 30ºC under a stream of pure dry nitrogen before use.
Reduction and alkylation protocol
Reduction and alkylation protocols were carried as per Street et al, 1996 . Whole venom and collected HPLC fractions were reduced by incubation for 30 min at 37ºC 8 in a solution of ~100µl of reduction reagent (10mM Tris-HCL pH 8.0, 1mM di-Na EDTA, 10mM dithiothreitol, 8M urea). Reduced venom fractions were then carboxyamidomethylated with iodoacetamide to protect the cysteine thiol groups and to readily identify the number of cysteines per peptide chain by mass difference. This was done by mixing an aliquot of the reduced venom fraction with 0.25 volumes of 0.25M iodoacetamide in 0.25M Tris-HCl at pH 8.0.
Edman Sequencing
Full and partial Edman sequencing of isolated peptides was undertaken at the Australian Proteome Analysis Facility.
Trypsin Digestion
Venom fractions from HPLC were evaporated to dryness and reconstituted in 25mM ammonium bicarbonate. Trypsin (sequencing grade, Sigma Chemicals) was added at approximately one fiftieth of the amount of the venom peptide, and the samples were incubated at 37 O C for 4 hours with occasional shaking, and either immediately analysed by HPLC-MS or stored at -50˚C until analysis.
Tandem Mass Spectrometry
Structural information on the peptides was obtained by ion trap tandem mass spectrometry, using a default collision energy of 45%. Molecular clusters of various charge states for the main peptides were targeted to gain maximum structural information. Microsoft Excel spreadsheets of m/z values of the various charge states of predicted key peptide ions based on published structures were generated to facilitate interpretation of the data. Additional data was obtained by Q-TOF MS analyses undertaken on a Micromass instrument at the Australian Proteome Analysis Facility.
Results:
Venom samples from several different batches (either different batches of venom to be used therapeutically or samples that were taken immediately following venom collection) were analysed, and all gave broadly similar peptide profiles. More than fifty peptides were readily detected, all in the 4kDa to 9kDa range. The venom samples were dominated by just a few peptides, and a typical chromatogram is shown in Figure 2 . Good correlation between LC-UV data and LC-MS data indicated that the majority of the peptides were apparently detected in the LC-MS runs.
From deconvolution of electrospray spectra both with and without 'supercharging', the main peptide in both fresh and stored samples (Peak B in Fig. 2 ) was found to have a molecular weight of ~5608 Da (unless otherwise specified, molecular weights listed refer to the averaged rather than monoisotopic weights); from here on for convenience this peptide is referred to as 'pilosulin 3'. Direct MS/MS data of pilosulin 3 was beyond direct sequencing due to its expected complexity, and no immediate correlation with the published major peptides was apparent. However, on the theory that this major peptide might contain the previously reported pilosulin 2 as a disulfide complex, the y ions (Roepstorff and Fohlman, 1984) were calculated for the neutral losses from the N-terminal end of pilosulin 2 from such a complex. These ions were observed for the first 10 residues from the N-terminus of pilosulin 2 (Fig   3) , initially supporting the presence of this known peptide. Reduction of pilosulin 3 resulted in peptides of ~3155 and ~2457 Da, confirming it as a heterodimeric peptide.
However, the predicted peptides were ~3212 Da (pilosulin 2) and either ~2400 or pilosulin 2 at ~3269 Da also strongly supported this assignment.
The 2457 Da peptide (hereafter referred to as 'pilosulin 3b') was subsequently isolated by HPLC as its carboxyamidomethylated derivative and fully sequenced by N-terminal Edman degradation. This resulted in the unequivocal 23 amino acid sequence,
which was unrelated to either Myr p 1 or Myr p 2. Evidence from both Q-TOF and ion trap tandem MS of this peptide strongly supported this sequence, and also indicated that the C-terminus was amidated, resulting in a calculated mass of 2457. and indicated that pilosulin 3 consisted of an antiparallel alignment of the des-Gly 27 -pilosulin 2 and pilosulin 3b chains. MS/MS data from m/z 519.2 was consistent with the expected peptide, with many ions directly assignable to this trypsin fragment diagnostic for antiparallel alignment (Fig 6) .
Trypsin cleavage products of native pilosulin 3 also supported the des-Gly 27 -pilosulin 2 sequence, with strong singly charged ions (monoisotopic values) at m/z 561 Another variant of pilosulin 3 had a molecular weight of ~5667 Da. This coeluted with pilosulin 3 and from reduction was found to be comprised of des-Gly 27 -pilosulin 2 and a ~ 2514 Da variant of pilosulin 3b which also coeluted with it. Tandem MS data indicated this to have an additional C-terminal glycine. This variant was typically about 20% of the abundance of pilosulin 3.
Pilosulin 3 (Peak B, Tang et al., 1993; Dongre, 1996) .
Subsequences starting from position 7 of pilosulin 1, as described above, were also observed in a slightly degraded stored sample that had initially had no pilosulin 1. If these were derived from the 6067 Da peptide, this indicated the difference of the variant from pilosulin 1 was in the first 6 residues. This made post-translational modification a less likely explanation due to the reported residues in these positions variant also more abundant than pilosulin 1.
14 Discussion:
This work has confirmed previous theories that the major peptide in jack jumper venom is a disulfide complex. We have found this complex be to comprised of a previously unreported subsequence from Myr p 2 and a novel smaller peptide with Cterminal amidation. N-terminal sequencing has previously been used to identify Myr p 1 and Myr p 2 derived polypeptides (Donovan et al., 1996) . The 8 cycles used would have been insufficient to detect the lack of a glycine residue, as predicted from the known cDNA sequence, at the C-terminal of des-Gly 27 -pilosulin 2.
Although most allergic sera appear to bind to peptides derived from Myr p 1 and Myr Neither isoelectric focusing and/or 2D SDS-PAGE would be likely to be useful in these separations, and this underlines the importance of HPLC in the separation of such closely related peptides.
The possibility of genetic variation explaining the apparent difference from published data was considered. We analysed venom samples from several different sources within Tasmania and an earlier reference sample from Victoria that was used by 
Figure 4
Ion trap product ion spectrum from the [M+3H] 3+ ion at m/z 1053 of the larger peptide (~3155 Da) obtained after reduction of peak B ('pilosulin 3'). This was ~57
Da lower than expected for pilosulin 2; interpretation of the tandem MS data from first principles and trypsin digest peptides indicated that it was consistent with desGly 27 -pilosulin 2 with C-terminal amidation, for which some assignments are shown. 
Individual ion assignments are derived from this.
Figure 6
Ion trap product ions and their assignments from the diagnostic trypsin cleavage product:
from pilosulin 3 giving unequivocal data on the alignment of the two chains . Capital letters represent peptide sequences originating from ACK derived from des-Gly 27 -pilosulin 2, lower case represents sequences originating from GTCVLVK derived from pilosulin 3b. 
